Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report

Fig. 1

ctDNA analysis can discriminate the status of different tumours in a patient with both melanoma and colorectal cancer. Levels of BRAF and KRAS ctDNA (green) inform of the status of melanoma and colon cancer respectively. Clinical partial response (PR) and complete response (CR) annotations are indicative of melanoma response to pembrolizumab as measured by RECIST on CT imaging. PET scan images associated with four different timepoints with differential BRAF and KRAS ctDNA levels

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us